...the Journal of Translational Medicine. ERCell has exclusive rights to ERCs from Medistem in Russia. ERCell LLC...

...50 million, 100 million and 200 million intramuscular ERC in about 15 patients with CLI. ERCell...
...Chinese market. Medistem and Jia Fu are initially focusing on CLI (see BioCentury, Feb. 27). ERCell LLC...

...have no other treatment options. ERCell has exclusive rights to ERC from Medistem in Russia. ERCell LLC...

...can be used for regulatory approval in Russia and the U.S. Terms were not disclosed. ERCell...
...cells, which are in Phase II testing to treat heart failure, from Medistem in Russia. ERCell LLC...

...dose-escalation Phase I trial evaluating ERC in CLI patients. Earlier this year, Medistem and partner ERCell LLC...

...Medistem and partner ERCell began the double-blind Phase II RECOVER-ERC trial to evaluate 50 million, 100...
...have no other treatment options. ERCell has exclusive rights to ERC from Medistem in Russia. ERCell LLC...